Dihydroartemisinin/miR-29b combination therapy increases the pro-apoptotic effect of dihydroartemisinin on cholangiocarcinoma cell lines by regulating Mcl-1 expression

Hui Hu1,A,D, Zongding Wang2,B, Chunlu Tan1,C,E, Xubao Liu1,A,D, Hao Zhang3,A,E, Kezhou Li3,A,F

1 Department of Traumatology, Central Hospital of Chongqing University, Chongqing Emergency Medical Center, China
2 Department of General Surgery, People’s Hospital of Fengjie, Chongqing, China
3 Departments of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, China

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation; D – writing the article; E – critical revision of the article; F – final approval of the article

Abstract

Background. Cholangiocarcinoma is a malignant tumor that originates from the neoplastic transformation of bile duct epithelial cells.

Objectives. To investigate the role of DHA and miR-29b on the proliferation and apoptosis of cholangiocarcinoma cells, and to explore whether DHA exerted its role through the miR-29b/Mcl-1 signaling pathway.

Material and methods. Human cholangiocarcinoma cell lines HUCCT-1 and FRH201 were treated with dihydroartemisinin (DHA) and DHA+miR-29b. The inhibitory effects of DHA and miR-29b on proliferation were detected using MTT assay. The effects of DHA and miR-29b on apoptosis were detected using flow cytometry (FCM). The mRNA and protein expressions of Mcl-1L and Mcl-1S were evaluated with reverse transcriptase polymerase chain reaction (RT-PCR) and western blotting, respectively.

Results. The DHA increased miR-29b expression in HUCCT-1 and FRH201 cells. The MTT assay showed that DHA+miR-29b combination therapy promoted the inhibition effects on the proliferation of HUCCT-1 and FRH201 cells. The FCM results revealed that DHA and miR-29b combination therapy increased the apoptosis of HUCCT-1 and FRH201 cells. The RT-PCR and western blotting analysis found that DHA+miR-29b combination therapy significantly decreased Mcl-1L expression and increased Mcl-1S expression in both HUCCT-1 and FRH201 cells. The Mcl-1S:Mcl-1L ratio was notably higher in the DHA+miR-29b combination therapy group than in the control group and DHA therapy group, in both HUCCT-1 and FRH201 cells.

Conclusions. The DHA and miR-29b have a pro-apoptotic effect on cholangiocarcinoma cells through the DHA/miR-29b/Mcl-1 pathway, possibly by upregulating the expression of the pro-apoptotic protein Mcl-1S and thus increasing the proportion of Mcl-1S protein among the total amount of Mcl-1 protein.

Key words: cholangiocarcinoma, miR-29b, dihydroartemisinin, Mcl-1
Introduction

Cholangiocarcinoma is a malignant tumor that originates from the neoplastic transformation of bile duct epithelial cells, with a particularly high prevalence in Eastern Asia. The malignancy is usually diagnosed at an advanced stage and is already inoperable; compared with other gastrointestinal tumors, it has a poorer response to chemotherapy. While no major advance has been made in investigating pathogenesis and establishing therapy of cholangiocarcinoma, the anti-tumor activity of dihydroartemisinin (DHA) has been widely recognized. Compared with artemisinin, dihydroartemisinin is more water-soluble, more absorbable and more effective against malaria. A recent study has demonstrated that DHA can promote apoptosis of tumor cells by changing cell autophagy.

The protein product encoded by Mcl-1 is a member of the Bcl-2 anti-apoptosis gene family. After transcription, this gene can produce a variety of transcripts through different splicing approaches. Specifically, the longest transcript-encoded gene product, myeloid cell leukemia Mcl-1L, can improve cell survival by inhibiting apoptosis, while the shorter gene product, Mcl-1S, has a pro-apoptotic effect and induces cell death. The miRNAs are a class of single-strand, noncoding small RNA molecules (19–25 nucleotides) which play a critical role in various processes, including cell growth, tissue differentiation, and the development and progression of malignant tumors. By complete or incomplete complementary pairing with the mRNA 3’ untranslated region (UTR) of target genes, they can inhibit or block the translation of target genes without affecting mRNA stability. Abnormal expression is often closely associated with abnormal apoptotic signaling pathways of tumor cells. The overexpression of miR-29b in cells results in a decreased Mcl-1 protein expression. Also, miR-29b expression is elevated in normal immortalized bile duct cells and decreased in malignant cholangiocarcinoma cell lines. The regulation of endogenous miRNA (e.g., miR-29) may provide a new treatment for cholangiocarcinoma. In our previous study, we found that DHA affected the expression of the apoptosis-associated protein Mcl-1 through multiple mechanisms, and that DHA therapy increased the Mcl-1:S:Mcl-1L protein ratio, thus inducing apoptosis in cholangiocarcinoma cells (QBC939).

Material and methods

Cell lines and main reagents

HUCC-T-1 and FRH0201 cell lines were obtained as a courtesy of the Cell Center of Hsiang-yu Medical College, Hunan, China. The DHA was purchased from Sciphar Biotechnology Co. Ltd. (Xian, China). Tetrazolium salt MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide), dimethyl sulfoxide (DMSO), Triton-100 and TRizol were purchased from Sigma Chemical Co. (St. Louis, USA). The miR-29b and its transfection kit were purchased from Guangzhou RiboBio Co. Ltd. (Guangzhou, China). Fetal bovine serum was purchased from Zhejiang Tianhang Biological Technology Co. Ltd. (Huzhou, China). RPMI-1640 culture medium and trypsin were purchased from Gibco (Grand Island, USA). A BCA protein assay kit was purchased from Beyotime (Haimen, China). Mcl-1 gene primers and probes were purchased from Sangon Bio-tech (Shanghai, China), and Mcl-1 antibody was sourced from Bioss (Beijing, China).

Cell culture and treatment

The HUCC-T-1 and FRH0201 cell lines were cultured at 37°C in an atmosphere of 5% CO₂ in RPMI-1640 medium containing 10% bovine calf serum and 100 U/mL of a penicillin-streptomycin solution, as specified by the American Type Culture Collection (Manassas, USA). The cells grew adherently and were passaged every 2–3 days. During cell passage, the old culture medium was removed and the cells were washed twice with phosphate-buffered saline (PBS). After the cells were digested with 0.25% trypsin, they were centrifuged at 1,000 rpm for 7 min, re-suspended in fresh medium and seeded into tissue culture flasks. After this step, 5 nmol of lyophilized miR-29b RNA powder was dissolved in 250 μL of sterilized deionized distilled water to prepare 20 μM of stock solution. After the fibroblasts were at the 2nd and 3rd passages, they were subcultured and inoculated in six-well plates. After the cells were at 60–70% confluence, miR-29b RNA was added; the cells were then further cultured in a constant-temperature incubator (5% CO₂ at 37°C).

Detection of the inhibitory effect of DHA on proliferation using an MTT assay

We performed the MTT assay in order to choose the best DHA concentration – one that would be effective and low-toxic. We found that 20 μmol/L of DHA met the requirement. The cells were divided into 3 groups: a control group, treated with 0.1% DMSO only (0 μmol/L DHA); a DHA therapy group, treated with 20 μmol/L of DHA; and a DHA+miR-29b combination therapy group, treated with 20 μmol/L of DHA and miR-29b. Six duplicate wells were set up for each group. HUCC-T-1 and FRH0201 cells in the logarithmic growth phase were collected. After cell
counting, the cells were inoculated into 96-well plates and routinely cultured for 24 h (with 10^4 cells in 200 μL each well). The DHA was added to a final concentration of 20 μmol/L for the DHA group. For the control group, an equal volume of 0.1% DMSO was added; for the 3rd group, DHA was added to a final concentration of 20 μmol/L, together with miR-29b and a transfection agent. The mixture was cultured at 37°C in an environment with saturated humidity and 5% CO₂ for 12 h, 24 h and 48 h. Each well was treated with 20 μL of MTT and then cultured for a further 4 h before the culture was terminated. The culture supernatant was discarded and 150 μL of DMSO was added to each well, followed by discoloration and oscillation for 10 min, so that the crystalline material was dispersed homogeneously. Absorbance was measured spectrophotometrically at 490 nm, and the growth inhibition rate was calculated.

Detection of apoptosis using flow cytometry and caspase 3/7 activity

apoptosis assay

The harvested cells were inoculated in 25-cm² culture flasks (15 mL/well). After routine culturing for 24 h, they were grouped as described for the MTT assay, with 6 duplicate wells in each group. In the experimental group, the cells were treated with 20 μmol/L of DHA and then cultured at 37°C in an environment with saturated humidity and 5% CO₂ for 12 h, 24 h and 48 h. The HUCCT-1 and FRH0201 cells were digested with 0.25% trypsin. After the mixture was suspended and centrifuged at 1,000 rpm for 5 min and the supernatant was discarded, the cells were washed twice with 0.01 mol/L of PBS. After the cells were fixed in precooled 70% ethanol at 4°C for 1 h, the mixture was centrifuged at 1,000 rpm for 5 min; then, the supernatant was discarded and the cells were washed twice with 0.01 mol/L of PBS. Add 1 mL of 0.01 mol/L PBS, followed by the addition of RNAase A and propidium iodide to a final concentration of 50 μg/mL for the HUCCT-1 cells and 100 μg/mL for the FRH0201 cells. Then, the mixture was stored in the dark at 4°C for 30 min. Finally, the cells were examined using flow cytometry (FCM). We also used a Caspase 3/7 Activity Apoptosis Assay Kit (E607103-0200; Sangon Biotech) to detect apoptosis by evaluating the relative fluorescence units.

Detection of Mcl-1 mRNA expression using reverse transcriptase polymerase chain reaction (RT-PCR)

β-actin was used as an internal control. The experimental grouping was the same as in the MTT assay. Total RNA isolation is briefly described below. In a two-milliliter tube with mechanically disrupted tissue sample, 1 mL of TRIzol was added, vortexed well, and incubated for 5 min at room temperature. Chloroform was added (0.2 mL per 1 mL of TRIzol) for homogenization. The sample was vortexed very well and incubated for 3 min at room temperature. Then, the samples were centrifuged at maximum speed on table microcentrifuge for 5 min at +4°C. The aqueous phase was transferred to a fresh microcentrifuge 2 mL tube with an equal volume of chloroform, vortexed well and then spun at maximum speed on table microcentrifuge for 5 min. The aqueous phase was transferred to a fresh microcentrifuge two-milliliter tube with an equal volume of 2-propanol, vortexed well and then spun at maximum speed on table microcentrifuge at room temperature for 10 min at +4°C. The pellets were washed once with 1.5 mL of 70% ethanol and spun at maximum speed on table microcentrifuge for 5 min. Next, the pellets were dissolved in 400 μL of 1 x TE at 55°C for about 10 min, with vortex. An equal volume of 10 M LiCl was added and the solution was chilled at –20°C for several hours (overnight). Afterwards, the solution was spun at maximum speed on table microcentrifuge for 10 min at +4°C. The supernatants were carefully removed and discarded. The pellets were then washed with 1.5 mL of 70% ethanol, vortexed well and micro-centrifuged, and the ethanol was discarded. Next, the pellets were dissolved in 200 μL of fresh milliQ water. Finally, 2 μg RNA was used for the RT-qPCR experiments.

With mRNA as the template, cDNA was synthesized using random hexamer primers. Based on the sequences of 2 transcripts of Mcl-1 in GenBank (MCLI-001, representing Mcl-1L, and MCLI-002, representing Mcl-1S), the primer and probe sequences of Mcl-1-related genes and the β-actin gene were designed as follows: upstream primer sequence of Mcl-1L – 5’-TTTGGCTACGGAGAAGAGG-3’, downstream primer sequence of Mcl-1L – 5’-TTCCGAA-GCATGTCCTTGGAGA-3’ (597-bp sequence fragment); upstream primer sequence of Mcl-1S – 5’-CCGCTTGGAGAGATGGAGA-3’; downstream primer sequence of Mcl-1S – 5’-CAGCGAGAAGGA-3’ (382-bp sequence fragment); upstream primer sequence of miR-29b – 5’-GT-TTCTACATGTTGGTTAGAT-3’, downstream primer sequence of miR-29b – 5’-GAACACTGTATTCAATGGT-3’ (61-bp sequence fragment); upstream primer sequence of β-actin – 5’-GAAGATCAGATCATTGCTC-3’, downstream primer sequence of β-actin – 5’-TACCTC-TGCTTGGATCCA-3’, probe – 5’-FAM-CTGCTCA-CTCCAGCGA-TAMRA-3’ (111-bp sequence fragment). The amplification conditions were as follows: initial denaturation at 94°C for 2 min, followed by 45 cycles of denaturation at 94°C for 20 s, annealing at 53°C for 30 s and extension at 60°C for 40 s. After the reaction was completed, Sequence Detection software v. 1.2.3 (Applied Biosystems, Foster City, USA) was used to analyze the threshold cycle (Ct) values of each sample. The specificity of PCR was judged according to the agarose gel electrophoresis and melting curves. The 2 reverse transcription quantitative polymerase chain reaction (RT-PCR) experiments. Relative quantitative analysis was performed based on the 2ΔΔCt method.
Detection of Mcl-1 protein expression with western blotting

The collected cells were uniformly seeded in 75-cm² culture plates (10 mL/well) and inoculated for 24 h. The grouping was the same as described in the MTT assay. After the cells were cultured at 37°C in an environment with saturated humidity and 5% CO₂ for 48 h, the old culture medium was discarded, and the cells were washed twice with 0.01 mol/L of PBS. In each well, 0.01 mol/L of PBS was added, and the cells were collected and centrifuged at 1,000 rpm for 5 min. Protein extracts were obtained by homogenizing the samples in lysis buffer (R0278; Sigma-Aldrich, Welwyn Gardens City, UK), followed by centrifugation at 4°C at 13,000 rpm for 15 min. Protein concentration was determined with the BCA protein assay method (23227; Thermo Fisher Scientific, Loughborough, UK). Equal amounts of protein (20 μg) were loaded per lane for electrophoresis. The separated proteins were transferred to polyvinylidene difluoride (PVDF) membranes, then blocked at room temperature for 3 h and inoculated at 4°C overnight. The membranes were washed, and the mixture was treated with rabbit anti-human Mcl-1 primary antibody. After inoculation at 37°C for 2 h, blocking solution and goat anti-rabbit IgG secondary antibody were added. Following inoculation at 37°C for 2 h, the mixture was held in a shaking water bath with 1X PBS 3 times (5 min each). After color development and photography, the expression of Mcl-1L, Mcl-1S, and β-actin was analyzed using Quantity One software v. 4.4.0 (Bio-Rad Laboratories, Inc., Hercules, USA).

Statistical analysis

The measurement data are presented as means ± standard deviation (SD). Comparison of the means between 2 groups was performed using Student’s t-test. A p-value <0.05 was considered to indicate a statistically significant difference.

Results

Effects of DHA on miR-29b expression level in HUCCT-1 and FRH201 cells

We used DHA to treat the HUCCT-1 and FRH201 cells, and then evaluated miR-29b expression. The DHA therapy significantly increased the expression of miR-29b at 48 h in the HUCCT-1 cells compared with the level in the control group (Fig. 1A). The expression of miR-29b in the FRH201 cells began to increase after 24 h, and the level of miR-29b was significantly higher than that of the control group after 48 h (Fig. 1B).

DHA and miR-29b combination therapy promoted the inhibition effects on the proliferation of HUCCT-1 and FRH201 cells

As shown using MTT assay, treatment with DHA (20 μmol/L) or DHA and miR-29b for 12 h significantly inhibited the proliferation of HUCCT-1 cells, and such inhibitory effects increased over time. Statistical analysis revealed that the inhibition rate significantly differed between the DHA+miR-29b and DHA groups at 12 h, 24 h and 48 h (p < 0.01, Fig. 2A).

Treatment with DHA for 12 h significantly inhibited the proliferation of FRH0201 cells, and DHA+miR-29b combination therapy for 24 h significantly inhibited the proliferation of FRH0201 cells (Fig. 2B). Such inhibitory effects became more apparent over time, and the inhibition rate reached 87.3% at 48 h. Statistical analysis revealed that cell proliferation was significantly inhibited in the DHA+miR-29b group at 24 h, and in both the DHA and DHA+miR-29b groups at 48 h (p < 0.01, Fig. 2B). In addition, the FRH0201 cell growth inhibition rates were also significantly higher in the DHA+miR-29b group when compared with those in DHA group at 24 h and 48 h (p < 0.05, Fig. 2B).

Fig. 1. Effects of DHA on miR-29b expression in HUCCT-1 and FRH201 cells. A. Effects on HUCCT-1 cells. B. Effects on FRH201 cells

* p < 0.05 vs control group.
Effects of DHA therapy and DHA+miR-29b combination therapy on apoptosis of HUCCT-1 and FRH201 cells

The detection of apoptosis using FCM and caspase-3 relative fluorescence units (RFU) showed that, in comparison with the control group, treatment with 20 μmol/L of DHA alone or DHA+miR-29b combination therapy significantly increased the apoptosis of HUCCT-1 cells at 24 h and 48 h (Fig. 3A,C; p < 0.01). The apoptosis rate at 48 h was significantly higher in the combination therapy group than in the DHA group (Fig. 3A). Compared with the control group, treatment with 20 μmol/L of DHA alone or with DHA+miR-29b significantly increased the apoptosis rate of FRH201 cells at 24 h and 48 h (Fig. 3B and 3D; p < 0.01). The apoptosis rate at 24 h and 48 h was significantly higher in the combination therapy group than in the DHA group (Fig. 3B,D; P < 0.01).

Effects of DHA therapy and DHA+miR-29b combination therapy on Mcl-1 mRNA expression

Reverse transcriptase fluorescence quantitative PCR (qPCR) revealed that Mcl-1L and Mcl-1S genes were expressed in the HUCCT-1 and FRH0201 cells. In the HUCCT-1 cell line, Mcl-1L gene expression significantly decreased 24 h after treatment with 20 μmol/L of DHA. Compared with the DHA therapy group, the DHA+miR-29b combination therapy group had significantly lower Mcl-1L gene expression (Fig. 4A). The Mcl-1S gene expression level increased; in particular, it significantly increased 48 h after DHA therapy and 24 h and 48 h after DHA+miR-29b combination therapy. The Mcl-1S expression levels were significantly higher in the DHA+miR-29b combination therapy group than in the DHA therapy group at 24 h and 48 h (Fig. 4B). The Mcl-1S:Mcl-1L ratio increased in the DHA+miR-29b group at all time points. In particular, it was significantly higher at 24 h and 48 h in the DHA+miR-29b group than in the control and DHA groups (Fig. 4C).

In the FRH0201 cell line, Mcl-1L gene expression also decreased after DHA therapy and DHA+miR-29b combination therapy. In particular, it was significantly lower at 24 h, 48 h and 72 h after DHA therapy and 72 h after DHA+miR-29b combination therapy (Fig. 4D). Mcl-1S gene expression increased in each treatment group. In particular, it was significantly higher in the DHA therapy group at 48 h and 72 h and in the combination therapy group at 24 h, 48 h and 72 h. Compared with the DHA group, Mcl-1S expression was significantly higher at 24 h, 48 h and 72 h in the DHA+miR-29b group (Fig. 4E). Compared with the control group, the Mcl-1S:Mcl-1L ratio increased in the treatment groups at different times. In particular, it was significantly higher in the DHA group at 48 h and 72 h and in the DHA+miR-29b group at 24 h and 48 h. Compared with the DHA therapy group, Mcl-1S expression significantly increased at 24 h and 48 h in the combination therapy group (Fig. 4F).

Effects of DHA therapy and DHA+miR-29b combination therapy on Mcl-1 protein expression profiles in HUCCT-1 and FRH0201 cells

Western blotting analysis confirmed the presence of Mcl-1L and Mcl-1S protein expression in HUCCT-1 and FRH0201 cells. In the HUCCT-1 cell line, DHA therapy and DHA+miR-29b combination therapy significantly decreased Mcl-1L protein expression, whereas Mcl-1S protein expression was increased (Fig. 5A,B). The Mcl-1S:Mcl-1L ratio was significantly higher in the DHA and DHA+miR-29b groups (Fig. 5C).

In the FRH0201 cell line, Mcl-1L protein expression was also significantly decreased after DHA therapy (Fig. 5D,E).
After DHA+miR-29b combination therapy, Mcl-1L protein expression was significantly higher than that after DHA therapy (Fig. 5D,E). The Mcl-1S protein expression level was significantly higher in each treatment group, and it was significantly higher in the combination therapy group than in the DHA therapy group (Fig. 5D,E). The Mcl-1S:Mcl-1L ratio was significantly higher in the treatment groups compared with the control group, and it was significantly higher in the combination therapy group than in the DHA therapy group (Fig. 5F).

**Discussion**

The DHA has a variety of potent anti-tumor effects. However, whether DHA can suppress cholangiocarcinoma or induce apoptosis of cholangiocarcinoma cells remains unclear. As a key regulator of Mcl-1 gene expression, we speculated that miR-29b may play a synergistic role with DHA in suppressing the growth of cholangiocarcinoma cells, although its underlying mechanism requires further investigation. In our current experiment, treatment with DHA and miR-29b decreased the proliferation of cholangiocarcinoma cells over time, along with an increase in cell growth inhibition rate. The proliferative activity of cholangiocarcinoma cells negatively correlated with the duration of DHA therapy, showing obvious proliferation-suppressing and apoptosis-promoting effects.

Tumorigenesis is associated with uncontrolled cell proliferation and apoptosis. Suppressing tumor-cell proliferation and inducing apoptosis are key methods for controlling and treating tumors, as well as being required indicators in screening for anti-cancer drugs. Many signal regulatory pathways are involved in apoptosis. For instance, p53 may activate apoptosis, and Bcl-2 and Bcl-XL – which belong to the anti-apoptosis family – can suppress apoptosis. These pathways can ultimately increase the release of mitochondrial cytochrome C and enhance activation of downstream caspases, which ultimately induces apoptosis. As a member of the Bcl-2 apoptosis regulator gene family, the anti-apoptosis gene Mcl-1 has similar sequence and functions as other Bcl-2 genes and
plays a key role in apoptosis. The Mcl-1 gene has 4 transcripts – Mcl-1-001–003 and Mcl-1-201; Mcl-1-003 does not encode protein products, whereas Mcl-1-001 is the corresponding mRNA of Mcl-1L and Mcl-1-002 is the corresponding mRNA of Mcl-1S. Although Mcl-1L and Mcl-1S are encoded by the same gene, they have opposite functions: the former is pro-apoptotic and the latter is anti-apoptotic. Mcl-1 pre-mRNA undergoes alternative splicing events to produce 2 proteins – the splicing variant Mcl-1S and the non-spliced Mcl-lL. Thus, in normally growing

![Fig. 4. Effects of DHA therapy and DHA+miR-29b combination therapy on mRNA expression of Mcl-1L and Mcl-1S. A. Effects of DHA therapy and DHA+miR-29b combination therapy on Mcl-1L mRNA expression at different time points. B. Effects of DHA therapy and DHA+miR-29b combination therapy on Mcl-1S mRNA expression at different time points. C. Changes in Mcl-1S:Mcl-1L ratio at different time points. D. Effects of DHA therapy and DHA+miR-29b combination therapy on Mcl-1L mRNA expression at different time points. E. Effects of DHA therapy and DHA+miR-29b combination therapy on Mcl-1S mRNA expression at different time points. F. Changes in Mcl-1S:Mcl-1L ratio at different time points.](image-url)

* p < 0.05 vs control group.
tumor cells, the expression of Mcl-1L is higher than that of Mcl-1S. Therefore, Mcl-1L is also known as Mcl-1. The ratio between Mcl-1S and Mcl-1L determines the fate of Mcl-1-expressing cells.

The anti-apoptotic protein Mcl-1 is highly expressed in cholangiocarcinoma cells, suggesting that the development of cholangiocarcinoma is closely correlated with the dysregulated expression of Mcl-1. In our previous study, we found that DHA induced apoptosis of QBC939 cells by affecting the apoptosis-related protein Mcl-1; as a result, the proportion of Mcl-1S in Mcl-1 was significantly higher. Meanwhile, the proliferation of QBC939 cells was markedly suppressed and apoptosis was enhanced. It was speculated that the occurrence of QBC939 apoptosis could be attributed to abnormal Mcl-1 protein expression due to the effect of DHA, and the proportion of Mcl-1L and Mcl-1S proteins in cells determines the fate of cells.

The Mcl-1 mRNA expression profile was also affected by the intervention. The mRNA for the synthesis of the Mcl-1S protein was significantly higher in the DHA-treated cholangiocarcinoma cells, along with a significant increase in the Mcl-1S protein expression level. As a result, the proportion of Mcl-1S in Mcl-1 was significantly higher. It was therefore speculated that DHA might induce the apoptosis of cholangiocarcinoma cells by upregulating the proportion of Mcl-1S in Mcl-1. To rule out experimental error in a single cell line, to validate whether DHA has a definite pro-apoptotic effect on cholangiocarcinoma cells, and to confirm whether the changes in Mcl-1-related expression promote apoptosis, in the current study, we used 2 cholangiocarcinoma cell lines: HUCCT-1 and FRH0201. Our experiments confirmed that DHA had potent growth-inhibiting and apoptosis-promoting effects on these 2 cholangiocarcinoma cell lines; meanwhile, DHA therapy significantly increased Mcl-1S expression in these 2 cell lines. These findings were consistent with our previous study on QBC939 cells.

Mott et al. reported that the expression of miR-29b was higher in a human immortalized, non-malignant cholangiocyte H69 cell line, but was decreased in a malignant cholangiocarcinoma KMCH cell line. When miR-29b was overexpressed in KMCH cells, the protein expression of Mcl-1, an anti-apoptotic Bcl-2 family member, was significantly lower, along with increased sensitivity to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). Many studies have confirmed that the downregulated expression of miR-29b in malignant cholangiocarcinoma cells is directly associated with the high expression of anti-apoptotic Mcl-1 protein in tumor cells. The miR-29b can also directly exert its effect on Mcl-1 gene 3′-UTR, whose overexpression, however, has no obvious effect on Mcl-1 mRNA. The expression of miR-29b is low in normally growing tumor cells. Many studies have shown that the expression of Mcl-1 is controlled by the small endogenous RNA molecule miR-29, and that the high expression of miR-29 markedly decreases the expression of Mcl-1L in cholangiocarcinoma cells. In our current study, we applied miR-29b to transfect the DHA-treated cholangiocarcinoma cells and found that...
DHA+miR-29b combination therapy markedly affected the mRNA expression profiles of Mcl-1 in both cell lines. More specifically, it significantly increased the expression level of mRNA, directing the synthesis of the Mcl-1S protein and thus increasing the Mcl-1S:Mcl-1L ratio. Flow cytometry revealed that DHA therapy and DHA+miR-29b combination therapy significantly increased the apoptosis of cholangiocarcinoma cells in a time-dependent manner. The pro-apoptotic effect was more prominent in the combination therapy group than in the DHA therapy group. Our experiment also showed that the inhibitory effects of DHA and DHA+miR-29b on the proliferation of cholangiocarcinoma cells were achieved by inducing apoptosis, and that the pro-apoptotic effect could be enhanced after combination therapy with miR-29b.

In summary, our study confirmed that DHA and miR-29b have a pro-apoptotic effect on cholangiocarcinoma cells, which may be because the DHA/miR-29b/Mcl-1 pathway changes the Mcl-1 gene expression profile by upregulating the expression of the pro-apoptotic protein Mcl-1S, thus increasing the proportion of Mcl-1S protein among the total Mcl-1 protein. However, due to the complexity of the cancer cell signaling pathways and their regulatory mechanisms, more relevant studies from different perspectives are warranted.

ORCID iDs
Kezhou Li https://orcid.org/0000-0002-5340-1129
Hui Hu https://orcid.org/0000-0002-2772-7387
Zongding Wang https://orcid.org/0000-0002-1952-546X
Chunlu Tan https://orcid.org/0000-0002-1440-0430
Xubao Liu https://orcid.org/0000-0002-6266-7519
Hao Zhang https://orcid.org/0000-0003-1912-6036

References